essence semaglutide (#wegovy/#ozempic) has better results, thus far, in its phase 3 fatty liver trial than its previous phase 2 trial it seems. 72-week data presented at The Liver Meeting 2024: American Association S5 - E26.1 - Looking
Description
The data in the study reinforces the significant costs associated with weight loss products
This favorable body composition effect adds value beyond the scale number
December 16, 2020
Yes, nausea is the most common side effect of semaglutide, and the likelihood of experiencing nausea increases with higher doses
